Bicalutamide
- Generic Name
- Bicalutamide
- Brand Names
- Casodex
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14F4N2O4S
- CAS Number
- 90357-06-5
- Unique Ingredient Identifier
- A0Z3NAU9DP
- Background
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
- Indication
Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.
- Associated Conditions
- Metastatic stage D2 Prostatic carcinoma
- Associated Therapies
- -
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 397
- Registration Number
- NCT00004054
- Locations
- 🇺🇸
Lutheran General Cancer Care Center, Park Ridge, Illinois, United States
🇺🇸Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States
🇺🇸Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 983
- Registration Number
- NCT00004124
- Locations
- 🇺🇸
Cancer Care Center at Advocate Lutheran Hospital, Park Ridge, Illinois, United States
🇺🇸Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸Bismarck Cancer Center, Bismarck, North Dakota, United States
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 67
- Registration Number
- NCT00023829
- Locations
- 🇨🇦
Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 1386
- Registration Number
- NCT00003653
- Locations
- 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
🇨🇦Clinical Research Unit at Vancouver Coastal, Vancouver, British Columbia, Canada
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 306
- Registration Number
- NCT00002855
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 1579
- Registration Number
- NCT00005044
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Veterans Affairs Medical Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Mercy Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Burzynski Research Institute
- Registration Number
- NCT00003517
- Locations
- 🇺🇸
Burzynski Clinic, Houston, Texas, United States
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 3040
- Registration Number
- NCT00002651
- Locations
- 🇨🇦
Saskatoon Cancer Centre at the University of Saskatchewan, Saskatoon, Saskatchewan, Canada
🇨🇦McGill Cancer Centre at McGill University, Montreal, Quebec, Canada
🇨🇦Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada
Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 840
- Registration Number
- NCT00002874
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-09-02
- Target Recruit Count
- 819
- Registration Number
- NCT00021450
- Locations
- 🇫🇷
Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besancon, France
🇮🇪Saint Luke's Hospital, Dublin, Ireland
🇨🇾Bank Of Cyprus Oncology Centre, Nicosia, Cyprus
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.